申请人:Koch H. Tad
公开号:US20070275911A1
公开(公告)日:2007-11-29
The invention provides a prodrug platform technology for improving the therapeutic value of a variety of parent drug compounds by altering and improving drug characteristics such as aqueous solubility, hydrolytic stability, therapeutic index, toxicity profile, pharmacolcinetics and selectivity while allowing the potential for synthetic elaboration. The prodrug platform is particularly well suited for targeting therapeutic drugs, including anti-tumor drugs and antibiotics, to specific receptors on target cells (e.g., cancer cells and bacteria). The platform is a technology for providing an improved, preactivated form of a therapeutic drug, and for optionally targeting such drug to target cells or biological molecules. The invention is broadly applicable to many different therapeutic drugs, as well as to a variety of diseases and conditions, including a variety of forms of cancer and bacterial infections.
本发明提供了一种前药平台技术,通过改变和改进药物特性,如水溶性、水解稳定性、治疗指数、毒性谱、药代动力学和选择性,从而提高各种原始药物化合物的治疗价值,同时允许潜在的合成扩展。该前药平台特别适用于将治疗药物,包括抗肿瘤药物和抗生素,定向靶向到目标细胞(例如癌细胞和细菌)上的特定受体。该平台是一种提供改进的、预激活形式的治疗药物的技术,并可选择性地将该药物定向到目标细胞或生物分子。本发明广泛适用于许多不同的治疗药物,以及多种癌症和细菌感染等不同疾病和病况。